RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.

Fiche publication

Date publication

décembre 2019

Journal

Cancer imaging : the official publication of the International Cancer Imaging Society

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KIM Stephano , Mme HENRIQUES Julie

Tous les auteurs :
Lucidarme O, Wagner M, Gillard P, Kim S, Bachet JB, Rousseau B, Mazard T, Louvet C, Chibaudel B, Cohen R, Garcia-Larnicol ML, Gobert A, Henriques J, André T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31818317

Résumé

To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib according to RECIST 1.1, Choi, and modified Choi (mChoi) criteria in patients with metastatic colorectal cancer (mCRC).